Results 81 to 90 of about 2,211,934 (230)
Journal of Neuroendocrinology, Volume 37, Issue 3, March 2025.Abstract Peptide receptor radionuclide therapy (PRRT) using [177Lu‐DOTA0,Tyr3]octreotate (177Lu‐DOTATATE) represents an established treatment modality for somatostatin receptor‐positive, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumours (GEP NET) of grade 1 or 2.
Jelka Kuiper +4 more
wiley +1 more source
Syndrome Measurement Order for the [[7,1,3]] Quantum Error Correction Code [PDF]
arXiv, 2013 In this work we explore the accuracy of quantum error correction depending of the order of the implemented syndrome measurements. CSS codes require bit-flip and phase flip-syndromes be measured separately. To comply with fault tolerant demands and to maximize accuracy this set of syndrome measurements should be repeated allowing for flexibility in the ...
arxiv
Endocrine-Related Cancer, 2014 Serotonin produced by neuroendocrine tumors is believed to be a principal cause of the diarrhea in carcinoid syndrome. We assessed the safety and efficacy of telotristat etiprate, an oral serotonin synthesis inhibitor, in patients with diarrhea ...
M. Kulke +14 more
semanticscholar +1 more source
Journal of Neuroendocrinology, Volume 37, Issue 3, March 2025.The thera(g)nostic approach with somatostatin analog‐based agents extends beyond gastroenteropancreatic neuroendocrine tumors. Understanding tumor biological mechanisms is essential for optimizing treatment strategies. Abstract First isolated by Brazeau et al. in 1972, somatostatin (SST) is a neuropeptide known for regulating various signaling pathways
Giulia Santo +3 more
wiley +1 more source
Use of perioperative telotristat in a patient with carcinoid heart disease
Endocrinology, Diabetes & Metabolism Case ReportsCarcinoid heart disease is a rare complication of carcinoid syndrome, resulting in right-sided valvular heart disease and subsequent heart failure due to long-term exposure to vasoactive substances.
Maria Flynn +7 more
doaj +1 more source
The Oncologist, 2014 BACKGROUND Octreotide LAR is used in patients for control of carcinoid syndrome (CS) and other symptoms of hormone hypersecretion. The aim of this study was to examine reasons for octreotide LAR dose escalation and observe CS symptom improvement in ...
J. Strosberg +7 more
semanticscholar +1 more source
ECHOCARDIOGRAPHIC DIAGNOSTICS OF CARCINOID HEART DISEASE
Zdravniški Vestnik, 2002 Background. Carcinoid heart disease is a rare heart disease which affects endocard and heart valves on the right side of heart. It affects only patients with manifested carcinoid syndrome, which is thought to be the consequence of secretory active ...
Janez Ravnik +3 more
doaj
Bulletin of the National Research Centre, 2019 Background Carcinoids at atypical sites are rare and mostly asymptomatic. In the majority, they show normal levels of serotonin and its metabolites in plasma and urine, resulting in a relatively late diagnosis and hence guarded prognosis.
Karim G. Moustafa, Gamal M. Saied
doaj +1 more source
Correction of Data and Syndrome Errors by Stabilizer Codes [PDF]
arXiv, 2016 Performing active quantum error correction to protect fragile quantum states highly depends on the correctness of error information--error syndromes. To obtain reliable error syndromes using imperfect physical circuits, we propose the idea of quantum data-syndrome (DS) codes that are capable of correcting both data qubits and syndrome bits errors.
arxiv
Carcinoid Crisis–Induced Acute Systolic Heart Failure
JACC: Case Reports, 2020 Carcinoid crisis is a life-threatening manifestation of carcinoid syndrome characterized by profound autonomic instability in the setting of catecholamine release from stress, tumor manipulation, or anesthesia.
Manoj V. Maddali, MD +8 more
doaj